| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1009529981 |
| P356 | DOI | 10.1007/S00101-013-2233-3 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s00101-013-2233-3 |
| P698 | PubMed publication ID | 24275933 |
| P2093 | author name string | A E Goetz | |
| C Zöllner | |||
| E M Zeidler | |||
| P2860 | cites work | Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. | Q51426110 |
| The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. | Q51539980 | ||
| Genetics of malignant hyperthermia. | Q55274166 | ||
| Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects | Q60018974 | ||
| The hypoalgesic effect of tramadol in relation to CYP2D6* | Q60678409 | ||
| Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? | Q63241960 | ||
| [Enzymatic inactivation of isonicotinic acid hydrizide in human and animal organism] | Q73408831 | ||
| The relation between dose of succinylcholine and duration of apnea in man | Q74612912 | ||
| Impact of P-glycoprotein on clopidogrel absorption | Q79368527 | ||
| Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome | Q81272805 | ||
| [Genetics, pain and analgesia] | Q83178086 | ||
| Pharmacogenetics of beta-blockers | Q24644448 | ||
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing | Q27008360 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Identification of the gene for vitamin K epoxide reductase | Q28242592 | ||
| Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects | Q28247385 | ||
| Genetic determinants of dabigatran plasma levels and their relation to bleeding | Q28286777 | ||
| Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies | Q29616299 | ||
| The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma | Q33910403 | ||
| Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes | Q33914036 | ||
| Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data | Q33920644 | ||
| Gender differences in opioid-mediated analgesia: animal and human studies | Q33980288 | ||
| Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy | Q34019082 | ||
| First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. | Q34149952 | ||
| Anaesthetic deaths in a family | Q34251990 | ||
| Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists | Q34317254 | ||
| Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis | Q34564576 | ||
| Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial | Q34622955 | ||
| Assessing the economic impact of adverse drug effects | Q35154708 | ||
| Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population | Q35583944 | ||
| Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy | Q35603072 | ||
| Principles of pharmacogenetics--implications for the anaesthetist | Q35818955 | ||
| Pharmacogenetics of anesthetic and analgesic agents | Q36054508 | ||
| Effect of genetic factors on opioid action | Q37510506 | ||
| Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance | Q37635192 | ||
| The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor | Q37821752 | ||
| Managing new oral anticoagulants in the perioperative and intensive care unit setting. | Q38082271 | ||
| Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans | Q42284291 | ||
| Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement | Q43190644 | ||
| Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes | Q44028620 | ||
| A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine | Q44481071 | ||
| Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers | Q44884449 | ||
| The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? | Q45282857 | ||
| New issues in oral anticoagulants | Q46202593 | ||
| Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: prospective validation of a prescription model | Q46757256 | ||
| Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc | Q46868498 | ||
| P433 | issue | 11 | |
| P1104 | number of pages | 13 | |
| P304 | page(s) | 874-886 | |
| P577 | publication date | 2013-11-01 | |
| P1433 | published in | Anaesthesist | Q1192168 |
| P1476 | title | [Pharmacogenetics. Clinical relevance in anesthsiology] | |
| P478 | volume | 62 |
| Q40594454 | Terbinafine : Relevant drug interactions and their management | cites work | P2860 |
Search more.